^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ABL1 fusion

i
Other names: ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
8d
A multi-modal molecular characterization of the Philadelphia translocation featuring long read sequencing. (PubMed, Gene)
Using the Ph translocation as an example, long read sequencing is shown to be a promising alternative method to detect SV, revolutionizing detection of chromosomal translocation to a higher precision. A more comprehensive spectrum of SV can be resolved along with cytogenetic results, enabling precise diagnosis and personalized monitoring of haematological malignancies.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
9d
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent. (PubMed, Cell Biol Int)
This study compared responses of three commonly used CML cell lines (K562, LAMA84, KCL22) to five TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib) and a Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor commonly used in clinical settings. This comprehensive comparison provides valuable insights for refining preclinical models and enhancing translational relevance in CML research and treatment development. Understanding the diverse responses of CML cell lines to TKIs and STAMP inhibitor facilitates the selection of appropriate models for specific research questions, ultimately improving the accuracy and reliability of preclinical studies in CML.
Preclinical • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
dasatinib • imatinib • Iclusig (ponatinib) • Tasigna (nilotinib) • Bosulif (bosutinib)
9d
Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion. (PubMed, Leuk Res)
Our results indicate that adult patients with MPALBCR::ABL1 present with younger age and may have better survival outcomes than patients with AMLBCR::ABL1. In addition, our next-generation sequencing (NGS) data indicates that RUNX1 is frequently mutated in B/myeloid MPALBCR::ABL1 compared to AMLBCR::ABL1. Future studies are warranted to further elucidate the role of RUNX1 in this disease.
Journal
|
ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1)
|
ABL1 fusion
12d
A case of T-cell acute lymphoblastic leukemia with co-occurrence of NUP214-ABL1 fusion and tetraploidy: A T-ALL case with NUP214-ABL1 fusion and tetraploidy. (PubMed, Cancer Genet)
Despite receiving the protocol-guided induction chemotherapy, the patient did not respond favorably. The challenges in treating Ph-like T-ALL with rare genetic abnormalities, highlight the need of further research and personalized medication.
Journal
|
ABL1 (ABL proto-oncogene 1) • NUP214 (Nucleoporin 214)
|
ABL1 fusion
18d
A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and PAX5 mutation. (PubMed, Int J Hematol)
The stroma-dependent growth pattern of JMPAL-1 also provides a unique platform to study tumor-stromal interactions and their role in leukemic cell survival and drug resistance. Our study highlights the importance of establishing preclinical models such as JMPAL-1 and performing detailed cytogenetic analysis to develop targeted therapies in line with the pathogenesis of the disease.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene) • ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • MPO (Myeloperoxidase)
|
BRAF mutation • CDKN2A deletion • ABL1 fusion
21d
Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov)
P1, N=92, Recruiting, Andrew E. Place, MD | Trial completion date: Apr 2027 --> Jul 2028 | Trial primary completion date: Apr 2025 --> Jul 2026
Trial completion date • Trial primary completion date • Pan tumor
|
FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
|
KMT2A rearrangement • ABL1 fusion
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
21d
A Novel 5-Probe FISH Strategy is Better Equipped for a More Comprehensive and Cost-Effective Risk Stratification of BCP-ALL. (PubMed, Int J Lab Hematol)
We conclude that the proposed five-probe FISH strategy is better equipped to more comprehensively risk stratify BCP-ALL patients, with an increased ability to identify high hyperdiploidy and a subset of Ph-like-BCP-ALL.
Journal • HEOR • Cost-effectiveness
|
ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2)
|
ABL1 fusion
2ms
Genetic subtypes of B-cell acute lymphoblastic leukemia in adults. (PubMed, Blood)
Their relevance for risk classification, disease monitoring and therapeutic management, including in the context of B-cell-directed therapies, is discussed. This review advocates for continuing efforts to further improve our understanding of the biology of adult B-ALL to establish the foundation of future precision medicine in B-ALL.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
2ms
Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature. (PubMed, Front Oncol)
A 66-year-old Chinese female patient was diagnosed with chronic myeloid leukemia-chronic phase (CML-CP) expressing four BCR::ABL1 transcripts, including variant e16a2(V-e16a2), variant e13a2(V-e13a2), classical e13a2, and e14a2 transcripts. The patient was treated with flumatinib, a tyrosine kinase inhibitor (TKI).The variant transcripts reported exhibited a favorable response to TKI, and attention should be directed toward monitoring variant transcripts.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion • BCR expression
|
Hansoh Xinfu (flumatinib)
3ms
Diagnostic Ambiguity Caused by an Atypical e18a2 BCR::ABL1 Transcript in a Chronic Myeloid Leukemia Patient. (PubMed, Case Rep Hematol)
The use of a cryptic splice site in intron 1 of ABL1 led to the generation of an in-frame BCR::ABL1 fusion transcript. The diagnostic difficulties caused by this atypical variant and its implications for diagnostic routine are discussed.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
3ms
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study. (PubMed, Ann Hematol)
These findings highlight dPCR as a sensitive and accurate tool for monitoring MRD in CML patients, providing information for treatment management decisions, and potentially enhancing the selection of candidates for treatment-free remission. Further standardization of dPCR methodologies is warranted to leverage their benefits in clinical practice.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
3ms
Identification of a Novel RUNX1::STX2 Fusion in Mixed-Phenotype Acute Leukemia (MPAL) With BCR::ABL1. (PubMed, Mol Carcinog)
The RUNX1::STX2 fusion protein may act as the primary negative regulator of wild-type RUNX1, influencing normal cell differentiation and proliferation, consequently elevating the risk of leukemia. The gene fusion status of this patient is unique and complex, requiring further exploration to understand its functional significance in leukemia progression and treatment response.
Journal
|
ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1)
|
ABL1 fusion • BCR expression
4ms
Validation of the Cepheid Xpert BCR-ABL Ultra p210 and p190 Assays in Peripheral Blood and Bone Marrow Specimens (AMP 2024)
Excellent concordance was seen between the Xpert BCRABL Ultra p210 and p190 assays compared to our institutional RT-qPCR assay in PB/BM samples. The Xpert BCR-ABL Ultra p190 and p210 assays showed distinct benefits, including near full automation, quick setup time without laborious RNA extraction, and fast turnaround time. These advancements allow us to assess PB/BM samples for p190 and p210 transcripts with high sensitivity and specificity for diagnostic and therapeutic monitoring purposes.
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
ABL1 fusion
|
Xpert® BCR-ABL Ultra
4ms
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial (ASH 2024)
Samples derived from cases from both the experimental and the control arm, based respectively on ponatinib followed by blinatumomab and on a combination of imatinib and conventional chemotherapy. While some groups reported a higher predictive prognostic power of IG/TR monitoring, our findings do not confirm these data, also in view of the very low rate of relapses so far observed. Nevertheless, a double-hit strategy may be informative for MRD monitoring and possibly for the distinction between typical/lymphoid Ph+ ALL vs multilineage/CML-like Ph+ ALL.
IO biomarker
|
ABL1 (ABL proto-oncogene 1) • IKZF1 (IKAROS Family Zinc Finger 1)
|
ABL1 fusion
|
LymphoTrack® Dx IGH Assay • LymphoTrack® Dx IGK Assay
|
imatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)
5ms
Application of Gene Expression Microarray for the Classification of Ph-Like B-Cell Acute Lymphoblastic Leukemia. (PubMed, Int J Lab Hematol)
In summary, we demonstrate using a gene expression microarray for classifying Ph-like B-cell ALL and highlight VPREB1 as a potential biomarker for this disease.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • ABL1 (ABL proto-oncogene 1) • JAK1 (Janus Kinase 1) • CA6 (Carbonic Anhydrase 6) • CD9 (CD9 Molecule) • EPHA7 (EPH Receptor A7) • TCL1A (TCL1 Family AKT Coactivator A) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)
|
ABL1 fusion
5ms
A high proportion of germline variants in pediatric chronic myeloid leukemia. (PubMed, Mol Cancer)
We hypothesize that the interaction with the strong oncogene BCR::ABL1 may also favor the development of leukemia by weaker variants in the same genes. In pediatric patients, the germline variants of genes associated with clonal hematopoiesis may increase the likelihood that an incidental BCR::ABL1 translocation triggers the early manifestation of CML.
Journal
|
ABL1 (ABL proto-oncogene 1) • NOTCH1 (Notch 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KDM6B (Lysine Demethylase 6B)
|
ABL1 fusion
5ms
Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report. (PubMed, Ann Hematol)
No additional somatic mutations or kinase domain mutations were identified, thereby suggesting that the current case is indeed genetically homogeneous. This study provided strong evidence to support the idea that insertion-derived BCR::ABL1 fusions often involve complex chromosomal abnormalities that are overlooked by conventional cytogenetics but can be identified by a combination of conventional, molecular cytogenetics, and high-end NGS studies.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
6ms
Emerging fusion-associated mesenchymal tumours: a tabular guide and appraisal of five 'novel' entities. (PubMed, J Clin Pathol)
Here, we have provided a review of selected emerging mesenchymal neoplasms, which of these neoplasms will meet the threshold to be 'new entities' remains to be determined.
Review • Journal
|
ABL1 (ABL proto-oncogene 1) • YAP1 (Yes associated protein 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • NUTM1 (NUT Midline Carcinoma Family Member 1) • GAB1 (GRB2 Associated Binding Protein 1) • NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1)
|
ABL1 fusion • TFE3 fusion
6ms
A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia. (PubMed, Br J Haematol)
Can chemotherapy-free approaches, such as blinatumomab in conjunction with more potent TKIs, obviate the need for an allograft in high-risk patients?...Can salvage therapy and a subsequent allograft cure patients who relapse after not being transplanted in CR1? This manuscript reviews the latest data influencing contemporary management and discusses these controversies.
Review • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
Blincyto (blinatumomab)
6ms
A Rare Case of X-Linked Four-Way Philadelphia Chromosome Translocation with Therapeutic Challenges and Clonal Evolution. (PubMed, Clin Lab)
This case highlights the challenge of ACAs impacting CML treatment response and prognosis. Limited knowledge exists on complex Ph translocations involving the X chromosome, but this report contributes data for further research. Understanding ACA effects on therapeutic response and prognosis requires a detailed study of such complex chromosomal aberrations.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
ABL1 fusion • BCR-ABL1 E292V
|
dasatinib • imatinib • Tasigna (nilotinib)
6ms
Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia. (PubMed, Front Oncol)
The current availability of six different TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib) in clinical practice makes it important to know their efficacy and toxicity profile for treatment optimization. In summary, the latest research highlights the versatility of bosutinib in CML treatment and underscores its pivotal role in optimizing patient management in challenging cases. Continuing research and investigation will further establish bosutinib's place in the evolving landscape of CML therapy, offering an alternative for CML patients across different treatment stages.
Clinical data • Review • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
dasatinib • imatinib • Iclusig (ponatinib) • Tasigna (nilotinib) • Bosulif (bosutinib) • Scemblix (asciminib)
10ms
ZMIZ1::ABL1 Fusion: An Uncommon Molecular Event With Clinical Implications in Pediatric Cancer. (PubMed, Arch Pathol Lab Med)
Although the karyotype was complex, identifying the t(9;10)(q34.1;q22) translocation, ABL1 disruption, and ZMIZ1::ABL1 transcript enabled effective ABL1-targeted treatment. Our data support the use of tyrosine kinase inhibitors to treat ZMIZ1::ABL1-derived B-cell acute lymphoblastic leukemia.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
10ms
Multilineage involvement in KMT2A-rearranged B acute lymphoblastic leukaemia: cell-of-origin, biology, and clinical implications. (PubMed, Histopathology)
In summary, multilineage involvement is common in both BCR::ABL1-rearranged and KMT2A-rearranged B-ALL, which should be taken into consideration when interpreting the disease burden during the clinical course.
Journal
|
ABL1 (ABL proto-oncogene 1) • KMT2A (Lysine Methyltransferase 2A)
|
MLL rearrangement • ABL1 fusion
11ms
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with BCR::ABL1 fusion. (PubMed, EJHaem)
In conclusion, our results suggest that pre-transplant TKI could improve disease status before allo-HCT. Moreover, allo-HCT resulted in high OS, high LFS, low relapse, and low NRM rates in patients with AML with BCR::ABL1.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
11ms
Discontinuation of tyrosine kinase inhibitors before epiphyseal closure leading to improved short stature in pediatric chronic myelogenous leukemia (PubMed, Rinsho Ketsueki)
Due to intolerance, the tyrosine kinase inhibitor (TKI) was changed from imatinib to dasatinib to nilotinib. Growth suppression by TKIs is a problem in the management of pediatric CML. This case illustrates how improvement in severe short stature can be achieved by discontinuing TKI therapy before epiphyseal closure.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
dasatinib • imatinib • Tasigna (nilotinib)
12ms
Clinical analysis of allogeneic hematopoietic stem cell transplantation for seven cases of acute myeloid leukemia with BCR::ABL1 fusion (PubMed, Zhonghua Xue Ye Xue Za Zhi)
In addition, allo-HSCT could enhance the molecular response rate. Maintenance therapy post-HSCT with TKI could improve prognosis.
Journal
|
ABL1 (ABL proto-oncogene 1) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • PHF6 (PHD Finger Protein 6)
|
NPM1 mutation • RUNX1 mutation • ASXL1 mutation • PHF6 mutation • ABL1 fusion
12ms
The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia. (PubMed, J Hematop)
After treatment with imatinib for 4 months, the patient achieved complete cytogenetic response (CCyR) and early molecular response (EMR). This is the first report of complex chromosomal karyotype involving six-way translocation in CML; the combination of chromosome analysis and FISH techniques is an effective strategy in determining the karyotype result.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
imatinib
12ms
ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia. (PubMed, Sci Adv)
Profiling of ERG- and c-MYC-dependent gene expression and analysis of ChIP-seq data established ERG and c-MYC coordinate a regulatory network in BCR::ABL1 B-ALL that controls expression of genes involved in several biological processes. Prominent was control of ribosome biogenesis, including expression of RNA polymerase I (POL I) subunits, the importance of which was validated by inhibition of BCR::ABL1 cells by POL I inhibitors, including CX-5461, that prevents promoter recruitment and transcription initiation by POL I. Our results reveal an essential ERG- and c-MYC-dependent transcriptional network involved in regulation of metabolic and ribosome biogenesis pathways in BCR::ABL1 B-ALL, from which previously unidentified vulnerabilities and therapeutic targets may emerge.
Journal
|
ABL1 (ABL proto-oncogene 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ERG (ETS Transcription Factor ERG)
|
MYC expression • ABL1 fusion
|
pidnarulex (CX-5461)
1year
Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia. (PubMed, Int J Hematol)
ETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative.
Review • Journal
|
ABL1 (ABL proto-oncogene 1) • ETV6 (ETS Variant Transcription Factor 6)
|
ABL1 fusion • ETV6-ABL1 fusion
|
dasatinib
1year
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. (PubMed, J Natl Compr Canc Netw)
Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.
Clinical guideline • NCCN guideline • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
1year
Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction. (PubMed, Hematol Transfus Cell Ther)
T315I mutations have a high incidence in Ph-positive ALL patients even if the course of disease is short. In molecular biology, T315I mutation detection is indicated for CML patients not in remission.
Journal • Polymerase Chain Reaction • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • ABL1 (ABL proto-oncogene 1)
|
ABL1 T315I • ABL1 fusion
1year
Novel Four-Way Variant Translocation, t(1;9;22;16)(q21;q34;q11.2;q24), in a Patient with Chronic Myeloid Leukemia. (PubMed, Diagnostics (Basel))
Nested RT-PCR of the BCR::ABL1 gene revealed a major BCR::ABL rearrangement. The treatment with nilotinib achieved a complete hematologic, cytogenetic, and molecular response after 12 months.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
Tasigna (nilotinib)
1year
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response. (PubMed, J Clin Med)
This study aimed to determine the effect of transcript type on TFR in patients receiving frontline treatment with imatinib (IM) or second-generation TKI (2G-TKI)...In addition, cases with the e14a2 transcript type treated at least 119 months with IM presented a better TFR (p = 0.024). On the other hand, the type of transcript did not affect the cytogenetic or molecular response in 2G-TKI treated patients; however, the use of 2G-TKI may be associated with higher and earlier DMR in patients with the e14a2 transcript.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
imatinib
1year
Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report. (PubMed, Diagn Pathol)
The erythroid variant of CML is distinguished by the presence of t(9;22) (q34;q11.2) BCR::ABL1 in predominant erythroid precursors at different stages of maturation. In a myeloid neoplasm showing predominant erythroid hyperplasia without typical CML features, it is vital to correlate morphology and t(9;22) BCR::ABL1 cytogenetic testing for accurate diagnosis, and to prevent confusion with PEL transformation in CML.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
1year
Establishment of the Myeloid TBX-Code Reveals Aberrant Expression of T-Box Gene TBX1 in Chronic Myeloid Leukemia. (PubMed, Int J Mol Sci)
TBX1 forms an integral part of an oncogenic regulatory network impacting proliferation, survival, and differentiation. Thus, the data spotlight novel diagnostic markers and potential therapeutic targets for this malignancy.
Journal
|
ABL1 (ABL proto-oncogene 1) • FGF2 (Fibroblast Growth Factor 2) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • GATA1 (GATA Binding Protein 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MIR92A1 (MicroRNA 92a-1) • TBX1 (T-Box Transcription Factor 1)
|
ABL1 fusion
|
dasatinib • imatinib
1year
Exploration of treatment-free remission in CML, based on molecular monitoring. (PubMed, Cancer Med)
Currently, predictive indicators for treatment-free remission outcomes and recurrence are lacking in clinical practice. In future, treatment-free remission research should focus on combining the clinical indicators with molecular monitoring and biological markers to personalize patient conditions and guide clinicians to develop individualized treatment plans, so that more patients with CML can achieve safer and stabler treatment-free remission.
Review • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
over1year
PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. (PubMed, Cancers (Basel))
In this study, we investigated the effectiveness of targeting poly-ADP-ribose polymerase (PARP) in a model of BCR::ABL1 p190+ ALL, the most common isoform to afflict ALL patients, and demonstrated the use of experimental PARP inhibitor (PARPi), AZD2461, as a therapeutic option with cytotoxic capabilities similar to that of imatinib, the current gold standard in medical care. Overall, we demonstrate the effectiveness of PARPi in the treatment of BCR::ABL1 p190+ ALL cell models and that PARP1 is differentially expressed in patient samples. We hope our findings help expand the characterization of molecular profiles in ALL settings and guide future investigations into novel biomarker detection and pharmacological choices in clinical practice.
Journal • PARP Biomarker
|
ABL1 (ABL proto-oncogene 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
ABL1 fusion
|
imatinib • AZD2461
over1year
Chronic myeloid leukemia with sleep-related painful erections as a first symptom: a case report. (PubMed, J Med Case Rep)
We considered that the occurrence of sleep-related painful erections was related to chronic myeloid leukemia and the case might be secondary sleep-related painful erections.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
over1year
A Real-World Single-Center Report on the Effectiveness and Safety of Blinatumomab Treatment on Pediatric Acute Lymphoblastic Leukemia in China (ASH 2023)
Blinatumomab is an effective treatment for B-ALL MRD cleanup with a good safety profile. It may, however, not benefit patients with R/R B-ALL with high tumor loads before blinatumomab, and those who carry BCR: : ABL1 fusion gene. Studies with a larger sample size are needed to confirm the results.
Clinical • Real-world evidence • Real-world
|
ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
|
CD19 expression • ABL1 fusion
|
Blincyto (blinatumomab)
over1year
The Efficacy and Safety of Olverembatinib Combined with Monoclonal Antibodies As Salvage Therapy for RR B ALL with ABL1 Fusion Gene Positive (ASH 2023)
Recently, such pts have new hope with the wide application of a novel third-generation TKI Olverembatinib developed in China and Blinatumomab(CD19 antibody,BITE)and INOTUZUMAB OZOGAMICIN(CD22 antibody,Ino. For heavily treated RR ABL1+B ALL pts,including those after treatment with ponatinib and other TKICART and HSCT, Olverembatinib combined with monoclonal antibodies is effective and safe. In my cases, it is particularly noteworthy that one pts ,Ph like ALL with ABL1 FG, received Olverembatinib combination BITE and achieved a surprising response, so Olverembatinib may also be effective and safe for such pts. In addition, venetoclax may be used as a sensitizer for TKI or other antitumor drugs.
Clinical
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
|
CD19 expression • ABL1 T315I • CD22 expression • ABL1 fusion
|
Venclexta (venetoclax) • Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Nailike (olverembatinib)